Compare AIRG & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | NSRX |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 53.5M |
| IPO Year | 2016 | N/A |
| Metric | AIRG | NSRX |
|---|---|---|
| Price | $4.16 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.25 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 45.1K | 3.5K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,779,000.00 | N/A |
| Revenue This Year | $13.17 | N/A |
| Revenue Next Year | $17.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $3.99 |
| 52 Week High | $5.85 | $9.99 |
| Indicator | AIRG | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 41.33 |
| Support Level | $3.96 | N/A |
| Resistance Level | $4.36 | $6.39 |
| Average True Range (ATR) | 0.33 | 0.70 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 7.41 | 35.08 |
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.